HeYuan Bioscience: Net loss of 36.0459 million yuan in the first quarter of 2026.

Hego Biotech announced that its operating income in the first quarter of 2026 was 9.6281 million yuan, an increase of 132.39% year-on-year. The net loss attributable to shareholders of the listed company was 36.0459 million yuan, compared to a net loss of 48.1952 million yuan in the same period last year.